Back to results
US 8,597,637 B1Granted
Breast cancer therapy using an engineered respiratory syncytial virus
OwnerWeidong Zhang, Lixian Jiang +1inventors
InventorsWeidong Zhang, Lixian Jiang, Calvin Cao
Life of this patent
Estimating the term…
Abstract
The invention discloses an engineered oncolytic respiratory syncytial virus (RSV), NS1 gene deficient RSV, and its usage to treat breast cancer by killing cancer cells with in vitro and in vivo evidences.
Claims6
A method to treat breast cancer in a patient in need thereof, comprising:
- 1) suspending an engineered oncolytic respiratory syncytial virus (RSV) with the NS1 gene deleted in saline or medium, and
- 2) injecting the RSV suspension into the cancerous tissue, wherein the RSV infects and causes oncolysis to thereby treat the patient.
A method to treat breast cancer in a patient in need thereof comprising:
- 1) suspending an engineered oncolytic respiratory syncytial virus with the NS1 gene deleted, and further comprising the viral NS2, N, M, SH, G, F, M2-1, P, and L genes, in saline or medium, and
- 2) injecting the engineered RSV suspension into cancerous tissue, wherein the RSV infects and causes oncolysis to thereby treat the patient.
Dependencies are inferred from the claim text.